Our understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is progressing rapidly. Consider as recent as 2011, the US Food and Drug Administration BIA-ALCL safety communication was based solely on 60 known world cases. At that time, there was no consensus on whether BIA-ALCL actually existed, no established optimal diagnosis and treatment, and no understanding of the biology of the disease.1 Few surgeons and even fewer patients had ever heard of the disease. Eight years and 600 cases later, safety advisories from the US Food and Drug Administration have become an annual event, and updates are ubiquitous at most society meetings. Mindful of this past, we present the following Aesthetic Surgery Journal (...